DNMT1 and metabolic syndrome: Since aberrant methylation of metabolic gene promoters and overexpression of DNMTs has been established as one of the major key players in the pathophysiology of MetS, demethylating agents such as DNMT inhibitors appear to offer promise as potential therapeutic targets for MetS.